Pharmacogenetics and the pharmaceutical industry

Current Pharmaceutical Design

Volumn 16, Issue 2, 2010, Pages 238-244

  Raaijmakers, Jan A M ^a   Koster, Ellen S ^a   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CETUXIMAB; GEFITINIB; IRINOTECAN; PRAVASTATIN; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROSIS; BEHAVIOR; BIOLOGY; BLEEDING; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TARGETING; ENVIRONMENTAL FACTOR; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACOGENETICS;

EID: 77949484469     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790112746     Document Type: Review

References (88)

1. Mauad T, Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008; 14(1): 31-8.
2. The Global Initiative for Asthma (GINA); http://www.ginasthma.com/
3. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4(3): 253-62.
4. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178(4): 332-8.
5. Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5(4): 506-12.
6. Saha S, Siva R, Brightling CE, Pavord ID. COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition. Eur Respir J 2006; 27(4): 863-5.
7. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56(4): 1054-70.
8. FDA. Guidance for Industry: Pharmacogenomic Data Submissions, 2007. www.fda.gov/cder/drug/advisory/pergolide.htm
9. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356(1): 29-38.
10. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nat Genet 2005; 37(7): 671-81.
11. National Audit Office. Safety, quality, efficacy: regulating medicines in the UK. HC Sessions 2002-2003; 2003.
12. Charatan F. FDA advisory panels recommend Lotronex be put back on market. BMJ 2002; 324(7345): 1053.
13. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21(2): 89-103.
14. Deverka PA, McLeod HL. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin Pharmacol Ther 2008; 84(2): 191-3.
15. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006; 145(10): 749-57.
16. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005; 5(12): 977-85.
17. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49(4): 369-79.
18. Dudbridge F, Gusnanto A, Koeleman BP. Detecting multiple associations in genome wide studies. Hum Genomics 2006; 2(5): 310-7.
19. Jiang Z, Zhou Y. Using bioinformatics for drug target identification from the genome. Am J Pharmacogenomics 2005; 5(6): 387-96.
20. Rice TK, Schork NJ, Rao DC. Methods for handling multiple testing. Adv Genet 2008; 60: 293-308.
21. Lesko LJ, Salerno RA, Spear BB, Anderson DC, Anderson T, Brazell C, et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 2003; 43(4): 342-58.
22. McCarthy A, Kerr M, Abadie E, Chibout SD, Imbert G, Cohen N, et al. Report on the joint EFPIA, DIA and EMEA pharmacogenetics workshop: moving toward clinical application. Pharmacogenomics 2004; 5(6): 731-9.
23. Couzin J. Drug safety. Gaps in the safety net. Science 2005; 307(5707): 196-8.
24. Strom BL. How the US drug safety system should be changed. JAMA 2006; 295(17): 2072-5.
25. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281(9): 824-9.
26. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348(6): 529-37.
27. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119(6): 985-9.
28. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58(4): 694-702.
29. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92(4): 949-53.
30. Vallance P, Levick M. Drug discovery and development in the age of molecular medicine. Clin Pharmacol Ther 2007; 82(4): 363-6.
31. Hahn KK, Wolff JJ, Kolesar JM. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm 2006; 63(22): 2211-7.
32. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359(8): 789-99.
33. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008; 7(10): 807-17.
34. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427(6974): 537-41.
35. Oldenburg J, Bevans CG, Fregin A, Geisen C, Muller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98(3): 570-8.
36. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93(1): 23-6.
37. Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read 2001; 11(4): 222-6.
38. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23(10): 1603-14.
39. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359(9312): 1121-2.
40. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359(9308): 727-32.
41. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6): 568-79.
42. Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH, et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008; 8(6): 365-74.
43. Phillips EJ, Mallal SA. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 2008; 21(1): 16-24.
44. AIDS Info Website. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, 2008: http:/www.aidsinfo.nih.gov
45. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6(4): 246-54.
46. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338(2): 86-93.
47. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22(2): 168-70.
48. Telleria JJ, Blanco-Quiros A, Varillas D, Armentia A, Fernandez-Carvajal I, Jesus Alonso M, et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102: 857-861.
49. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 (Suppl 2): S28-31.
50. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12(7): 565-70.
51. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370(9605): 2118-25.
52. Fenech AG, Ebejer MJ, Felice AE, Ellul-Micallef R, Hall IP. Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects. Br J Pharmacol 2001; 133(1): 43-8.
53. Lipworth B, Koppelman GH, Wheatley AP, Le Jeune I, Coutie W, Meurs H, et al. Beta2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002; 57(1): 61-6.
54. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13(13): 1353-9.
55. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177-82.
56. King CR, Kraus MH, Aaronson SA. Amplification of a novel verbB-related gene in a human mammary carcinoma. Science 1985; 229(4717): 974-6.
57. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353(16): 1734-6.
58. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007; 7(2): 257-68.
59. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8(4): 307-25.
60. Higa GM. Targeting HER 1 and 2 in breast cancer with lapatinib. Oncol Rev 2008; 2(1): 21-28.
61. Mihaljevic A, Buchler P, Harder J, Hofheinz R, Gregor M, Kanzler S, et al. A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer. BMC Surg 2009; 9: 1.
62. Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003; 21(14): 2658-63.
63. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-39.
64. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497-500.
65. Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 2007; 120(6): 1239-47.
66. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27(12): 2091-6.
67. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 672-80.
68. Consortium WTCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447(7145): 661-78.
69. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39(7): 830-2.
70. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6(4): 304-12.
71. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate 2006; 66(10): 1013-28.
72. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5(9): 645-56.
73. Treppicchio WL, Mulligan G. Translation of biomarkers into clinical utility. Pharmacogenomics Pers Med 2008: 239-251.
74. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26(7): 1066-72.
75. Liggett SB. Pharmacogenetic applications of the human genome project. Nat Med 2001; 7(3): 281-3.
76. Lanfear DE, McLeod HL. Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician 2007; 76(8): 1179-82.
77. Consortium IH. A haplotype map of the human genome. Nature 2005; 437(7063): 1299-320.
78. Shannon W, Culverhouse R, Duncan J. Analyzing microarray data using cluster analysis. Pharmacogenomics 2003; 4(1): 41-52.
79. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487-91.
80. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7(5): 201-4.
81. Lai-Goldman M, Faruki H. Abacavir hypersensitivity: a model system for pharmacogenetic test adoption. Genet Med 2008; 10(12): 874-8.
82. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008; 83(5): 781-7.
83. Kirschner MW. The meaning of systems biology. Cell 2005; 121(4): 503-4.
84. Aderem A. Systems biology: its practice and challenges. Cell 2005; 121(4): 511-3.
85. Bansal AT, Barnes MR. Genomics in drug discovery: the best things come to those who wait. Curr Opin Drug Discov Dev 2008; 11(3): 303-11.
86. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res 2007; 67(18): 8511-8.
87. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 2007; 67(23): 11335-43.
88. Bromley CM, Close S, Cohen N, Favis R, Fijal B, Gheyas F, et al. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group. Pharmacogenomics J 2009; 9(1): 14-22.